Course curriculum

  • 1

    Medications

    • Absence seizures (July 2019)

    • Acute ischemic stroke - management - 4Qs (January 2019)

    • ACE inhibitor and ARB use in diabetes (July 2018)

    • ACE-inhibitor-associated cough (March 2019)

    • Acute kidney injury - 4Qs (July 2019)

    • Anemia in children - 3Qs (May 2020)

    • Antibiotic interactions - 3Qs (September 2018)

    • Anticholinergic toxicity (July 2019)

    • Anticoagulation and the surgical patient (January 2020)

    • Antidepressants and sexual dysfunction - 2Qs (May 2020)

    • Anxiety in adults - 3Qs (November 2019)

    • Aortic dissection - 2Qs (May 2020)

    • Aspirin and pre-eclampsia (July 2018)

    • Aspirin and primary prevention of cardiovascular disease - 2Qs (September 2019)

    • Aspirin therapy and diabetes (May 2019)

    • Asthma - management - 2Qs (January 2020)

    • Asthma in young children - 2Qs (January 2020)

    • Asthma treatment - 3Qs (July 2018)

    • Atrial septal defects (November 2019)

    • Atopic dermatitis - 3Qs (March 2020)

    • Atopic dermatitis in children - 2Qs (March 2020)

    • Attention deficit-hyperactivity disorder in adults - 3Qs (July 2018)

    • Bell's palsy - 2Qs (May 2019)

    • Barretts esophagus - 2Qs (March 2019)

    • Benign prostatic hyperplasia - 3Qs (January 2019)

    • Beta-blockers and cardiovascular disease - 2Qs (November 2018)

    • Beta-blockers - Perioperative (May 2020)

    • Bisphosphonates - duration of treatment (January 2019)

    • Breast cancer - chemoprophylaxis - 3Qs (July 2019)

    • Breast cancer - Genitourinary symptoms - 3Qs (January 2019)

    • Cat scratch disease (September 2019)

    • Central serous chorioretinopathy (November 2019)

    • Chlamydia in the newborn (January 2020)

    • Cholestatic pruritis - 2Qs (November 2019)

    • Chronic hypertension and pregnancy - 3Qs (March 2020)

    • Cirrhosis management - 3Qs (July 2018)

    • Clostridium difficile in children (November 2018)

    • Clostridium difficile - overview - 2Qs (November 2018)

    • Clostridium difficile - treatment -2Qs (September 2018)

    • Common cold - treatment (January 2019)

    • Community-acquired pneumonia in adults - outpatient - 2Qs (January 2020)

    • Community-acquired pneumonia - inpatient - 2Qs (January 2020)

    • Contraception and cardiovascular disease - 2Qs (May 2019)

    • Contraception and neurologic disease - 2Qs (March 2019)

    • Contraceptives in adolescents (July 2019)

    • Contraception in women with diabetes - 2Qs (May 2019)

    • COPD and Roflumilast (September 2018)

    • Corticosteroid-induced hyperglycemia - 3Qs (November 2019)

    • Crohn's disease - 3Qs (March 2019)

    • Cyanotic heart disease - 4Qs (March 2020)

    • Depression in adolescents (September 2019)

    • Diabetes in children (November 2020)

    • Digoxin toxicity (November 2018)

    • Diabetes - individualization of medications - 3Qs (November 2019)

    • Diabetes mellitus type 2 – prevention - 3Qs (May 2019)

    • Drug-induced angioedema - 2Qs (January 2019)

    • Drug-induced dermatology - 3Qs (January 2020)

    • Eclampsia prophylaxis (March 2020)

    • Eczema - Dyshidrotic (March 2020)

    • Emergency contraception - 4Qs (May 2019)

    • Eosinophilia - 2Qs (May 2020)

    • Epidural anesthesia in labor - 2Qs (May 2020)

    • Erythema multiforme (November 2019)

    • Erectile dysfunction - 4Qs (January 2019)

    • Evaluation of the patient with bleeding - 4Qs (January 2019)

    • Febrile seizures - 2Qs (May 2020)

    • Fluoroquinolones - adverse effects (July 2019)

    • Fluoroquinolones - adverse effects - 2Qs (November 2018)

    • Frontotemporal dementia - 2Qs (July 2019)

    • Galactogogues (July 2018)

    • Gastroesophageal reflux disease – infants (May 2019)

    • Gastroparesis - 3Qs (May 2020)

    • Gingival hyperplasia (November 2018)

    • Glycemic control - 3Qs (May 2019)

    • Group B strep - early onset disease - 2Qs (January 2020)

    • Group B strep - late onset disease (January 2020)

    • Group B strep screening and prophylaxis - 3Qs (January 2020)

    • Gynecomastia - 3Qs (September 2019)

    • Headache in pregnancy - 3Qs (July 2019)

    • Helicobacter pylori - 2Qs (November 2019)

    • Hepatitis A - pre- and post-exposure prophylaxis - 2Qs (March 2019)

    • Herpetic Esophagitis - 3Qs (November 2019)

    • Heroin (July 2018)

    • Hiccups (November 2019)

    • HIV in older adults (March 2020)

    • HIV during pregnancy and in infants - 2Qs (March 2020)

    • Human bite injuries - 2Qs (July 2019)

    • Hyalurons (January 2020)

    • Hydroxyurea and sickle cell disease - 2Qs (January 2019)

    • Hyperglycemia - Medication-induced - 2Qs (September 2019)

    • Hyperlipidemia - nonstatin treatment (September 2020)

    • Hypersomnia - 2Qs (May 2019)

    • Hypertension - Gestational - 3Qs (March 2020)

    • Hypertriglyceridemia - 2Qs (November 2018)

    • Hypoparathyroidism - 2Qs (November 2019)

    • Incretin-based therapy for type 2 diabetes mellitus (July 2018)

    • Influenza in high risk populations - 3Qs (May 2020)

    • Influenza in long-term care facilities - 2Qs (May 2020)

    • Inhaled antimuscarinics - 2Qs (March 2020)

    • Inhaled steroids in COPD (September 2019)

    • Intrauterine devices - hormonal (July 2018)

    • Intrauterine device - insertion - 2Qs (July 2018)

    • Intrauterine devices - problems/complications (July 2018)

    • Intrauterine device - removal (July 2018)

    • Ischemic stroke - management - 4Qs (November 2018)

    • Isolated systolic hypertension - 2Qs (May 2020)

    • Leukotriene receptor antagonists - 2Qs (November 2018)

    • Lung injury - Drug-induced - 3Qs (November 2019)

    • Male hypogonadism - 2Qs (November 2018)

    • Medication adherence (March 2019)

    • Medication errors in children (May 2019)

    • Menstrual migraine - 2Qs (May 2019)

    • Migraine - biologic agents (March 2020)

    • Migraine prophylaxis - 2Qs (November 2018)

    • Migraine prophylaxis - Pediatric - 2Qs (March 2020)

    • Migraine - treatment with triptans - 3Qs (September 2019)

    • Mycobacterium Avium Complex - 2Qs (July 2019)

    • Naltrexone (September 2020)

    • Neuroleptic Malignant Syndrome - 2Qs (July 2019)

    • NSAIDs and cardiovascular disease - 2Qs (January 2019)

    • Oral contraceptives and risk of venous thromboembolism (March 2020)

    • Oropharyngeal Candidiasis (July 2019)

    • Osteoarthritis – management - 2Qs (May 2019)

    • Osteoarthritis of the shoulder - 2Qs (January 2020)

    • Osteomyelitis - 3Qs (May 2019)

    • Osteoporosis - treatment with raloxifene (March 2019)

    • Parkinson's disease and impulse control disorders (November 2018)

    • Parkinsons disease - treatment - 2Qs (November 2019)

    • Penicillin allergy (September 2019)

    • Performance-enhancing drugs (March 2020)

    • Peripheral polyneuropathy - 2Qs (May 2020)

    • Prediabetes in adults - 2Qs (May 2020)

    • Preexposure prophylaxis in pregnancy (PrEP) (September 2019)

    • Probiotics (May 2020)

    • Progestin-only oral contraceptives (March 2020)

    • Prostatitis - 3Qs (July 2019)

    • Prosthetic joints and prophylaxis for dental procedures (March 2020)

    • Psoriasis comorbidities - 2Qs (March 2019)

    • Pulmonary sarcoidosis - 3Qs (May 2020)

    • Resistant hypertension - 2Qs (September 2018)

    • Salmonella infection (September 2019)

    • Schistosomiasis - 2Qs (January 2020)

    • Selective serotonin reuptake inhibitors (SSRIs) in pregnancy (September 2019)

    • Sinusitis - complications (November 2019)

    • Sodium-coupled glucose transporter-2 (SGLT2) inhibitors - 2Qs (March 2019)

    • Solitary functioning kidney in children - 2Qs (January 2019)

    • Spontaneous bacterial peritonitis - 2Qs (March 2020)

    • SSRI use and the effect on the newborn (September 2019)

    • Statins and primary prevention - 2Qs (July 2019)

    • Status epilepticus (September 2019)

    • Steroid use for preterm labor (September 2018)

    • Sudden hearing loss - 2Qs (July 2019)

    • Sudden sensorineural hearing loss - 2Qs (March 2020)

    • Sulfonylurea overdose - 2Qs (November 2019)

    • Systolic Blood Pressure Intervention Trial (SPRINT) (November 2018)

    • Thrombolysis after stroke - 2Qs (March 2020)

    • Thyroid medication – dosing - 2Qs (May 2019)

    • Tocolytics - 2Qs (July 2018)

    • Tramadol (generic, Ultram) (January 2019)

    • Tranexamic acid (generic, Lysteda) (March 2019)

    • Tularemia - 2Qs (September 2019)

    • Type 1 diabetes in children - 3Qs (September 2020)

    • Type 1 diabetes mellitus - Pediatric - 2Qs (January 2020)

    • Type 2 diabetes in children and adolescents - 3Qs (September 2019)

    • Tuberculosis - extrapulmonary - 3Qs (January 2019)

    • Tuberculosis - latent infection - 2Qs (May 2020)

    • Understanding lipid recommendations - 2Qs (September 2018)

    • Unprovoked venous thrombosis - 4Qs (November 2019)

    • Urinary incontinence - 2Qs (November 2018)

    • Urinary retention - 2Qs (November 2018)

    • Use of Varenicline (generic, Chantix) (September 2019)

    • UTI in nonpregnant women - 2Qs (March 2020)

    • Venous thromboembolism and malignancy - 2Qs (January 2019)

    • Vulvovaginal candidiasis in pregnancy (September 2019)

    • Xerostomia - 2Qs (May 2020)